menu
    • menu
    [{"orgOrder":0,"company":"Kivu Bioscience","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"KIVU-107","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Kivu Bioscience","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Kivu Bioscience \/ Organovo Holdings","highestDevelopmentStatusID":"5","companyTruncated":"Kivu Bioscience \/ Organovo Holdings"},{"orgOrder":0,"company":"Kivu Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"KIVU-107","moa":"PTK7","graph1":"Undisclosed","graph2":"Approved FDF","graph3":"Kivu Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kivu Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Kivu Bioscience \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Kivu Bioscience

    Menu

    Kivu Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kivu Bioscience

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Kivu Bioscience

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KIVU-107

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

                            Details : KIVU-107 is an antibody-drug conjugate, which is currently being evaluated in Phase I clinical studies for the treatment of Endometrial Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            November 14, 2025

                            Lead Product(s) : KIVU-107

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kivu Bioscience

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Kivu Bioscience

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KIVU-107

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Organovo Holdings

                            Deal Size : $92.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Kivu Bioscience Raises $92M to Advance Antibody-Drug Conjugates

                            Details : The financing will aims to support the clinical development of multiple antibody-drug conjugate (ADC) programs, which include KIVU-107. It is being evaluated for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : KIVU-107

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Organovo Holdings

                            Deal Size : $92.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth